Who can use Ibrance(palbociclib)?

The specific medical conditions the drug is approved to treat.

Approved Uses

IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients whose disease has progressed after endocrine therapy. It is also approved for use with inavolisib and fulvestrant in patients with endocrine-resistant, PIK3CA-mutated advanced breast cancer following recurrence after adjuvant endocrine therapy.